Our Blog

The Cochrane Review – FAQ

Reframing the Evidence in Alzheimer’s Disease 1. What is the Cochrane review? The Cochrane Collaboration is an independent group that reviews medical research to help summarise what […]

Everything You Need to Know About p-Tau217: The New Innovative  Blood Test for Alzheimer’s Pathology

Alzheimer’s disease and related forms of dementia remain among the most challenging conditions in modern medicine, affecting millions of people worldwide. One of the greatest hurdles has […]

REFRAMING THE EVIDENCE Disease-Modifying Treatments in Alzheimer’s: A New Era of Clinical Possibility

Visit our Frequently Asked Questions Here. The Cochrane Collaboration review of 17 randomised controlled trials involving 20,342 participants has contributed to recent debate about anti-amyloid therapies in […]

Diet, Genetics and Brain Health: What a New Study Reveals About Alzheimer’s Risk

Emerging research continues to reshape how we understand the relationship between diet and cognitive health. A recent study led by Jakob Norgren and colleagues offers a more […]

A Breakthrough in Treating Degenerative Brain Diseases

In her compelling TEDx Athens Salon talk, delivered as part of the TEDx Global Idea Search, Dr Emer MacSweeney, CEO and Consultant Neuroradiologist at Re:Cognition Health, presented […]

Alzheimer’s Fingerprick Tests: Why Blood-Based Biomarker Trials Matter

Early diagnosis has long been one of the greatest challenges in Alzheimer’s disease. For decades, clinicians have been forced to rely on expensive brain scans, invasive lumbar […]

Dr Steve Allder Speaks at TEDxAthens Salon: Reimagining Dementia

At TEDxAthens, consultant neurologist Dr Steve Allder delivered a powerful talk that challenged everything we think we know about dementia and longevity. Speaking with rare clarity and […]

Why We Are at a Turning Point in Treating Alzheimer’s

Dr Emer MacSweeney, Co-Founder, CEO and Consultant Neuroradiologist at Re:Cognition Health, was interviewed, recently, by Healthcare Today about one of the most pressing issues in modern medicine: […]

A Setback for NHS Access – But Re:Cognition Health Offers Hope for Alzheimer’s

Turning Setback Into Progress This week’s decision by NICE (the National Institute for Health and Care Excellence) to reject funding for two groundbreaking Alzheimer’s drugs Leqembi™ (lecanemab) […]

Patient Story

“The entire experience of participating in the clinical trial has been exceptional. The team at Re:Cognition Health genuinely prioritises the wellbeing of their patients. Their understanding and […]